Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ATACAND HCT vs ONFI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ATACAND HCT is a combination of candesartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, increasing sodium, chloride, and water excretion, thereby reducing plasma volume and blood pressure.
GABA-A receptor positive allosteric modulator; increases the frequency of chloride channel opening in response to GABA.
Treatment of hypertension, for patients not adequately controlled on monotherapy.
Treatment of seizures associated with Lennox-Gastaut syndrome,Adjunctive therapy for other seizure types
One tablet orally once daily. Initial dose: 16 mg candesartan/12.5 mg hydrochlorothiazide. Titrate to maximum 32 mg candesartan/25 mg hydrochlorothiazide once daily.
Initial: 10 mg orally twice daily; may increase by 10 mg/day after 1 week to maintenance of 20–40 mg/day in two divided doses. Maximum: 60 mg/day.
Candesartan: ~9 hours (terminal). Hydrochlorothiazide: 6-15 hours (terminal, mean ~10 hours).
The terminal elimination half-life of clobazam is 36–42 hours. The active metabolite N-desmethylclobazam has a half-life of 71–82 hours. The long half-life permits once-daily dosing but also leads to slow accumulation; steady-state is achieved after 2–3 weeks.
Candesartan is primarily metabolized by hepatic O-deethylation via CYP2C9 to an inactive metabolite. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged by the kidneys.
Hepatic via CYP3A4 and CYP2C19; primary metabolite N-desmethylclobazam is active.
Candesartan: ~33% renal, ~67% biliary/fecal. Hydrochlorothiazide: >95% renal.
Clobazam (ONFI) undergoes extensive hepatic metabolism. Approximately 82% of the dose is eliminated in urine (as unchanged drug and metabolites) and about 11% in feces. Unchanged clobazam accounts for <1% of urinary excretion. The major metabolite, N-desmethylclobazam, is excreted primarily renally.
Candesartan: >99% (primarily albumin). Hydrochlorothiazide: 40-70% (primarily albumin).
Clobazam is approximately 80–90% bound to plasma proteins, primarily albumin.
Candesartan: 0.13 L/kg (extensive tissue distribution). Hydrochlorothiazide: 0.83-2.5 L/kg (distributes into plasma and red blood cells).
The apparent volume of distribution is approximately 100 L (range 77–120 L), or roughly 1.4 L/kg. This large Vd indicates extensive tissue distribution and accumulation in fatty tissues.
Candesartan: ~15% (absolute, prodrug conversion). Hydrochlorothiazide: ~70% (oral).
Oral bioavailability is nearly complete (>90%). Clobazam is well absorbed after oral administration with only minor first-pass metabolism.
Contraindicated if GFR <30 m L/min/1.73 m2. No adjustment for GFR 30-50 m L/min/1.73 m2. Use with caution and monitor renal function.
No specific GFR-based dose adjustments; use with caution in severe impairment (Cr Cl < 30 m L/min) due to potential for increased sedation.
Mild to moderate hepatic impairment (Child-Pugh A or B): No dose adjustment. Severe impairment (Child-Pugh C): Not recommended due to hydrochlorothiazide accumulation risk.
Mild to moderate (Child-Pugh A/B): Initial 5 mg orally twice daily; may increase by 5 mg/day after 1 week to maximum 20 mg/day. Severe (Child-Pugh C): Not recommended.
Safety and efficacy not established in pediatric patients (<18 years).
Clobazam (ONFI) for seizures: Age 2 to <6 years, body weight ≥12.5 kg: Initial 5 mg orally once daily; titrate to maintenance 5 mg twice daily. Age ≥6 years: Weight ≤30 kg: Initial 5 mg once daily; titrate to 5 mg twice daily (max 20 mg/day). Weight >30 kg: same as adult dosing. Administer with food.
No initial dose adjustment required. Use caution due to increased sensitivity to hypotension and electrolyte disturbances; monitor renal function and electrolytes.
Elderly (≥65 years): Initial 5 mg orally twice daily; increase slowly to lowest effective maintenance due to increased sensitivity and risk of falls. Avoid doses above 20 mg/day unless clearly necessary.
None.
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant use for patients for whom alternative treatment options are inadequate.
Fetal toxicity: Use in pregnancy can cause oligohydramnios, fetal renal dysfunction, and skull ossification defects. Discontinue as soon as possible when pregnancy is detected.,Hypotension: Symptomatic hypotension may occur in volume-depleted patients. Correct volume depletion before initiation.,Impaired renal function: Monitor renal function due to risk of acute renal failure, especially in patients with renal artery stenosis.,Electrolyte imbalances: Hydrochlorothiazide can cause hypokalemia, hyponatremia, hypomagnesemia, and hypercalcemia; candesartan can cause hyperkalemia.,Metabolic effects: Thiazides may increase serum cholesterol, triglycerides, and uric acid levels; may cause hyperglycemia.,Acute angle-closure glaucoma: Hydrochlorothiazide can cause acute transient myopia and acute angle-closure glaucoma.,Systemic lupus erythematosus: Thiazides have been reported to cause exacerbation or activation of SLE.,Non-melanoma skin cancer: Thiazide diuretics may increase risk; monitor for skin lesions.
Risk of respiratory depression, especially with opioids,Sedation and somnolence,Risk of abuse and dependence,Withdrawal seizures on abrupt discontinuation,Increased risk of suicidal thoughts or behavior
Hypersensitivity to candesartan, hydrochlorothiazide, or any component of the formulation.,Anuria (hydrochlorothiazide component).,Pregnancy (second and third trimesters).,Severe renal impairment (Cr Cl <30 m L/min).,Concomitant use with aliskiren in patients with diabetes mellitus.
Hypersensitivity to clobazam or any component of formulation,Severe hepatic impairment
Avoid salt substitutes containing potassium chloride unless approved by your doctor. Limit high-potassium foods (e.g., bananas, oranges, tomatoes) if hyperkalemia risk is present. Take hydrochlorothiazide with food or milk to reduce gastrointestinal upset. Grapefruit juice has no significant interaction with this combination.
Avoid grapefruit and grapefruit juice as they may increase clobazam levels. No other significant food interactions are known. CNS depressant effects may be potentiated by alcohol.
Pregnancy Category D. First trimester: potential fetotoxicity; second and third trimesters: ACE inhibitor exposure causes oligohydramnios, fetal renal dysfunction, skull ossification defects, and neonatal renal failure. Angiotensin receptor blocker (ARB) component: similar adverse effects. Thiazide diuretic: risk of fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances. Use contraindicated in pregnancy.
Pregnancy Category C. First trimester: increased risk of major malformations including cleft lip/palate (OR 2.0-3.0); second/third trimester: risk of neonatal withdrawal, hypotonia, poor feeding, respiratory depression, and hypothermia; consistent exposure may cause floppy infant syndrome. Late pregnancy exposure linked to neonatal benzodiazepine withdrawal syndrome.
Candesartan (ARB) and hydrochlorothiazide (HCTZ) are excreted in breast milk. M/P ratio not established for candesartan; HCTZ M/P ratio is approximately 0.6. HCTZ may suppress lactation. Use not recommended during breastfeeding due to potential adverse effects in the infant, including electrolyte imbalance, hypotension, and renal impairment.
Clobazam is excreted into breast milk; M/P ratio approximately 0.5-0.6. Accumulation possible in neonates; monitor for sedation, poor feeding, apnea. Avoid if infant has impaired hepatic function or low birth weight. American Academy of Pediatrics recommends caution; use lowest effective maternal dose.
Dose adjustments not applicable; drug is contraindicated in pregnancy. If unintentionally exposed, discontinue as soon as pregnancy is detected. No dose adjustment recommendations for pregnancy due to lack of safe use data.
Increased clearance during pregnancy (CYP3A4 induction); plasma concentrations may decrease by 30-50% in third trimester. Dose adjustments often required: monitor therapeutic response and consider dose increase by 50-100% in late pregnancy; postpartum reduce to prepregnancy dose over 1-2 weeks to avoid toxicity.
ATACAND HCT is a fixed-dose combination of candesartan (an angiotensin II receptor blocker) and hydrochlorothiazide (a thiazide diuretic). Monitor renal function and electrolytes, especially potassium and sodium, within 2 weeks of initiation and periodically thereafter. Avoid use in pregnancy; discontinue as soon as pregnancy is detected. May cause symptomatic hypotension, particularly in volume-depleted patients; correct volume depletion before starting. Can exacerbate gout due to thiazide-induced hyperuricemia. Not recommended for use with aliskiren in patients with diabetes or renal impairment (GFR <60 m L/min).
ONFI (clobazam) is a benzodiazepine indicated for seizures associated with Lennox-Gastaut syndrome. Titrate slowly to minimize sedation. Monitor for withdrawal symptoms upon discontinuation; taper over several weeks. Not recommended for use in patients with severe hepatic impairment (Child-Pugh C). For patients on other CNS depressants, consider dose reduction. Clobazam's active metabolite, N-desmethylclobazam, has a long half-life (36-46 hours) and can accumulate, especially in poor CYP2C19 metabolizers. In such patients, consider lower doses and monitor for excessive sedation.
Do not take if you are pregnant, plan to become pregnant, or are breastfeeding.,Take exactly as prescribed; do not skip doses or double up.,Drink adequate fluids to prevent dehydration unless instructed otherwise by your doctor.,Avoid alcohol and NSAIDs (e.g., ibuprofen) as they may increase side effects.,Report symptoms like lightheadedness, excessive thirst, muscle cramps, or irregular heartbeat.,Monitor blood pressure regularly at home and keep a log.,This medication may increase sensitivity to sunlight; use sunscreen and protective clothing.
Take ONFI exactly as prescribed; do not stop suddenly as withdrawal seizures may occur.,Avoid alcohol and other sedatives while taking this medication due to increased risk of drowsiness and respiratory depression.,Report any unusual mood changes, depression, or suicidal thoughts to your healthcare provider.,Do not drive or operate heavy machinery until you know how ONFI affects you, as it can cause dizziness and drowsiness.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss with your doctor before using ONFI.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ATACAND HCT vs ONFI, answered by our medical review team.
ATACAND HCT is a Angiotensin II Receptor Blocker / Thiazide Diuretic that works by ATACAND HCT is a combination of candesartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, increasing sodium, chloride, and water excretion, thereby reducing plasma volume and blood pressure.. ONFI is a Benzodiazepine Anticonvulsant that works by GABA-A receptor positive allosteric modulator; increases the frequency of chloride channel opening in response to GABA.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ATACAND HCT and ONFI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ATACAND HCT is: One tablet orally once daily. Initial dose: 16 mg candesartan/12.5 mg hydrochlorothiazide. Titrate to maximum 32 mg candesartan/25 mg hydrochlorothiazide once daily.. The standard adult dose of ONFI is: Initial: 10 mg orally twice daily; may increase by 10 mg/day after 1 week to maintenance of 20–40 mg/day in two divided doses. Maximum: 60 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ATACAND HCT and ONFI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ATACAND HCT is classified as Category C. Pregnancy Category D. First trimester: potential fetotoxicity; second and third trimesters: ACE inhibitor exposure causes oligohydramnios, fetal renal dysfunction, skull ossificati. ONFI is classified as Category C. Pregnancy Category C. First trimester: increased risk of major malformations including cleft lip/palate (OR 2.0-3.0); second/third trimester: risk of neonatal withdrawal, hypotonia. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.